Chief Executive Officer of the Pune-based Serum Institute Of India (SII) Adar Poonawalla on Monday said the company is expecting the vaccine for COVID-19 to be ready by the year-end.
The Institute has partnered with British-Swedish drugmaker AstraZeneca to manufacture and supply the vaccine being developed by the University of Oxford under which the SII will supply over a billion doses of vaccine in India, and to other developing and under-developed countries.
However, the approval for the vaccine from the Drug Controller General of India is still awaited.
The institute is expecting to get approval in next six months.The Oxford COVID-19 vaccine trial is currently in its Phase 3 or human trial stage, and will be administered to around 8,000 people in the U.K.
chief executive Poonawalla said while referring to another vaccine candidate from India ie Covaxin of Bharat Biotech, that the company is in no hurry to produce vaccine without proper actions and tests for safety and efficacy.Once they are confident about vaccine, they would launch the vaccine but that would be still 6 months away.
However Bharat Biotech is also confident about its candidate vaccine named Covaxin and has started phase-1 human trials enrolling about 375 patients for test. It is very unlikely that Corona vaccine to be out for masses before or on 15 August, despite the letter of ICMR since human trials may take up to 6-8 months to complete even after conducting only important tests and checks.
It is very positive for the country that we are seeing candidates for vaccine which are in human trials.The vaccine developed in country will be great opportunity for Indian institutes to once again lead the world in pandemic situation.